Regulus Therapeutics (RGLS) Earnings Date, Estimates & Call Transcripts $1.46 -0.10 (-6.41%) (As of 09/6/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateNov. 14EstimatedActual EPS (Aug. 8) -$0.17 Consensus EPS (Aug. 8) -$0.17 Conference Call TranscriptConference Call AudioEarnings Press Release Get Regulus Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for RGLS and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueRGLS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RGLS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. Regulus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.19)($0.11)($0.15)Q2 20242($0.13)($0.11)($0.12)Q3 20242($0.13)($0.12)($0.13)Q4 20242($0.13)($0.13)($0.13)FY 20248($0.58)($0.47)($0.53)Q1 20251($0.20)($0.20)($0.20)Q2 20252($0.20)($0.20)($0.20)Q3 20252($0.21)($0.20)($0.21)Q4 20252($0.23)($0.20)($0.22)FY 20257($0.84)($0.80)($0.82)RGLS Earnings Date and InformationRegulus Therapeutics last announced its earnings results on August 8th, 2024. The biopharmaceutical company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). Regulus Therapeutics has generated ($1.46) earnings per share over the last year (($1.46) diluted earnings per share). Earnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.80) to ($1.20) per share. Regulus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off prior year's report dates.Read More Regulus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/8/2024-($0.17)($0.17)-($0.17)-- 5/9/2024Q1 2024($0.15)($0.29)($0.14)($0.29)-- 3/21/2024Q4 2023($0.40)($0.40)-($0.40)-- 11/9/2023Q3 2023($0.36)($0.40)($0.04)($0.40)-- 8/8/2023Q2 2023($0.39)($0.37)+$0.02($0.37)-- 5/11/2023Q1 2023($0.41)($0.42)($0.01)($0.42)-- Get the Latest News and Ratings for RGLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/23/2023Q4 2022($0.49)($0.40)+$0.09($0.40)-- 11/10/2022Q3 2022($0.50)($0.50)-($0.50)-- 8/11/2022Q2 2022($0.46)($0.50)($0.04)($0.50)-- 5/12/2022Q1 2022($0.50)($0.50)-($0.05)-- 3/10/2022Q4 2021($0.50)($0.70)($0.20)($0.07)-- 11/10/2021Q3 2021($0.80)($1.00)($0.20)($0.10)-- 8/10/2021Q2 2021($0.80)($0.80)-($0.08)-- 5/13/2021Q1 2021($0.90)($0.80)+$0.10($0.08)-- 3/8/2021Q4 2020($1.40)($0.30)+$1.10($0.03)$0.02 million$5.00 million11/5/2020Q3 2020($2.10)($0.40)+$1.70($0.04)$0.51 million$5.00 million 8/13/2020Q2 2020($1.07)($2.3311)($1.2611)($0.23)--5/14/2020Q1 2020($1.20)($2.50)($1.30)($0.25)$10.00 million$6.00 million3/12/2020Q4 2019($2.40)($2.30)+$0.10($0.23)$0.02 million$0.02 million11/12/2019Q3($2.63)($2.60)+$0.03($0.26)$0.02 million$0.02 million Regulus Therapeutics Earnings - Frequently Asked Questions When is Regulus Therapeutics's earnings date? Regulus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on RGLS's earnings history. Did Regulus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Regulus Therapeutics (NASDAQ:RGLS) reported ($0.17) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.17). Learn more on analysts' earnings estimate vs. RGLS's actual earnings. How can I listen to Regulus Therapeutics's earnings conference call? The conference call for Regulus Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Regulus Therapeutics's conference call transcript? The conference call transcript for Regulus Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Regulus Therapeutics generate each year? Regulus Therapeutics (NASDAQ:RGLS) has a recorded net income of -$30.04 million. RGLS has generated -$1.46 earnings per share over the last four quarters. What is Regulus Therapeutics's EPS forecast for next year? Regulus Therapeutics's earnings are expected to decrease from ($0.80) per share to ($1.20) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Alimera Sciences Earnings Date Lexicon Pharmaceuticals Earnings Date XOMA Earnings Date Vanda Pharmaceuticals Earnings Date Rigel Pharmaceuticals Earnings Date Codexis Earnings Date Sangamo Therapeutics Earnings Date Achieve Life Sciences Earnings Date Agenus Earnings Date Verastem Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Is Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 EarningsNVIDIA: Analysts Bullish Ahead of Earnings - Is It a Buy Now? This page (NASDAQ:RGLS) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
